These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32586117)

  • 1. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting.
    Lukic M; Eleftheriadou M; Hamilton RD; Rajendram R; Bucan K; Patel PJ
    Eur J Ophthalmol; 2021 Jul; 31(4):1940-1944. PubMed ID: 32586117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting.
    Eleftheriadou M; Vazquez-Alfageme C; Citu CM; Crosby-Nwaobi R; Sivaprasad S; Hykin P; Hamilton RD; Patel PJ
    Am J Ophthalmol; 2017 Feb; 174():160-168. PubMed ID: 27746298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting.
    Eleftheriadou M; Gemenetzi M; Lukic M; Sivaprasad S; Hykin PG; Hamilton RD; Rajendram R; Tufail A; Patel PJ
    Ophthalmol Ther; 2018 Dec; 7(2):361-368. PubMed ID: 29982914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
    Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
    Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
    Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
    Demir N; Sevincli S; Kayhan B; Sonmez M
    Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
    Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
    Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study.
    Gascon P; Ramtohul P; Delaporte C; Kerever S; Denis D; Comet A
    Eur J Ophthalmol; 2022 Jan; 32(1):356-363. PubMed ID: 33779324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.